Circulating amounts of osteoprotegerin and RANK ligand: Genetic influence and relationship with BMD assessed in female twins

被引:38
作者
Abrahamsen, B [1 ]
Hjelmborg, JV
Kostenuik, P
Stilgren, LS
Kyvik, K
Adamu, S
Brixen, K
Langdahl, BL
机构
[1] Odense Univ Hosp, Dept Endocrinol, DK-5000 Odense, Denmark
[2] Univ So Denmark, Danish Twin Register, Odense, Denmark
[3] Amgen Inc, Thousand Oaks, CA 91320 USA
[4] Aarhus Univ, Aarhus Kommune Hosp, Dept Endocrinol C, DK-8000 Aarhus, Denmark
关键词
bone mineral density; RANK ligand; osteoprotegerin; genetics; twins;
D O I
10.1016/j.bone.2004.12.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Osteoprotegerin (OPG) is a circulating receptor that inhibits osteoclastogenesis by binding to RANK ligand (RANKL). OPG knock-out animals develop severe osteoporosis. Treatment with OPG lowers bone resorption and increases BMD. OPG production is influenced by a wide range of hormones and cytokines. The influence of genetic factors on circulating amounts of OPG and RANKL is not known. BMD has been demonstrated to have a high heritability and there is evidence also that bone turnover and bone loss rates are controlled at least in part by genetic factors. Objective. Assessing the genetic impact on serum OPG and RANKL in women and estimation of the relative contribution of this inheritance to the total heritability of BMD. Methods. 188 female twins (52 DZ and 42 MZ pairs) from the Danish Twin Registry were included in the study. Mean age was 35 years (range 19-64 years), average spine BMD was 1.04 +/- 0.11 g/cm(2). Serum levels of OPG and RANKL were measured by ELISA (Biomedica, Vienna, Austria). This register covers twins born in Denmark since 1870. Heritability and environmental influence was assessed using a maximum-likelihood model for genetic pleiotropy. Results. RANKL levels showed a negative correlation with age and lower values in smokers. OPG levels were higher in postmenopausal women. Heritability (h(2)) was 85% for spine BMD and 52% for serum RANKL after adjustment for age, smoking and BMT. By contrast, there was no significant genetic influence on OPG levels (h(2)=0, 95% CI: 0 to 0.31). Serum OPG was determined almost exclusively by individual environment (e(2) = 0.79), with a small, non-significant contribution from shared environment (c(2) = 0.21). Restricting analyses to the 158 premenopausal twins did not alter the findings. Conclusions. Serum OPG and RANKL levels have only a weak relation to BMD in healthy women. Phenotype correlations indicate that the genes that contribute to twin similarity for BMD are not genes regulating serum levels of RANKL or OPG. The weak correlation with BMD appears to consist in shared environmental factors. (c) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:727 / 735
页数:9
相关论文
共 52 条
[21]   Genome screen for quantitative trait loci underlying normal variation in femoral structure [J].
Koller, DL ;
Liu, GD ;
Econs, MJ ;
Hui, SL ;
Morin, PA ;
Joslyn, G ;
Rodriguez, LA ;
Conneally, PM ;
Christian, JC ;
Johnston, CC ;
Foroud, T ;
Peacock, M .
JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 (06) :985-991
[22]   OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis [J].
Kong, YY ;
Yoshida, H ;
Sarosi, I ;
Tan, HL ;
Timms, E ;
Capparelli, C ;
Morony, S ;
Oliveira-dos-Santos, AJ ;
Van, G ;
Itie, A ;
Khoo, W ;
Wakeham, A ;
Dunstan, CR ;
Lacey, DL ;
Mak, TW ;
Boyle, WJ ;
Penninger, JM .
NATURE, 1999, 397 (6717) :315-323
[23]   Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation [J].
Lacey, DL ;
Timms, E ;
Tan, HL ;
Kelley, MJ ;
Dunstan, CR ;
Burgess, T ;
Elliott, R ;
Colombero, A ;
Elliott, G ;
Scully, S ;
Hsu, H ;
Sullivan, J ;
Hawkins, N ;
Davy, E ;
Capparelli, C ;
Eli, A ;
Qian, YX ;
Kaufman, S ;
Sarosi, I ;
Shalhoub, V ;
Senaldi, G ;
Guo, J ;
Delaney, J ;
Boyle, WJ .
CELL, 1998, 93 (02) :165-176
[24]   Polymorphisms in the transforming growth factor beta 1 gene and osteoporosis [J].
Langdahl, BL ;
Carstens, M ;
Stenkjær, L ;
Eriksen, EF .
BONE, 2003, 32 (03) :297-310
[25]   Polymorphisms in the osteoprotegerin gene are associated with osteoporotic fractures [J].
Langdahl, BL ;
Carstens, M ;
Stenkjaer, L ;
Eriksen, EF .
JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 (07) :1245-1255
[26]   A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women [J].
Langdahl, BL ;
Knudsen, JY ;
Jensen, HK ;
Gregersen, N ;
Eriksen, EF .
BONE, 1997, 20 (03) :289-294
[27]   Parathyroid hormone stimulates TRANCE and inhibits osteoprotegerin messenger ribonucleic acid expression in murine bone marrow cultures: Correlation with osteoclast-like cell formation [J].
Lee, SK ;
Lorenzo, JA .
ENDOCRINOLOGY, 1999, 140 (08) :3552-3561
[28]   Association of methylenetetrahydrofolate reductase (MTHFR) polymorphism with bone mineral density in postmenopausal Japanese women [J].
Miyao, M ;
Morita, H ;
Hosoi, T ;
Kurihara, H ;
Inoue, S ;
Hoshino, S ;
Shiraki, M ;
Yazaki, Y ;
Ouchi, Y .
CALCIFIED TISSUE INTERNATIONAL, 2000, 66 (03) :190-194
[29]   Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor osteoprotegerin [J].
Mizuno, A ;
Amizuka, N ;
Irie, K ;
Murakami, A ;
Fujise, N ;
Kanno, T ;
Sato, Y ;
Nakagawa, N ;
Yasuda, H ;
Mochizuki, S ;
Gomibuchi, T ;
Yano, K ;
Shima, N ;
Washida, N ;
Tsuda, E ;
Morinaga, T ;
Higashio, K ;
Ozawa, H .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 247 (03) :610-615
[30]   PREDICTION OF BONE-DENSITY FROM VITAMIN-D RECEPTOR ALLELES [J].
MORRISON, NA ;
QI, JC ;
TOKITA, A ;
KELLY, PJ ;
CROFTS, L ;
NGUYEN, TV ;
SAMBROOK, PN ;
EISMAN, JA .
NATURE, 1994, 367 (6460) :284-287